Early Use of Botulinum Toxin in Spasticity Post Stroke.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01882556
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Sandwell & West Birmingham Hospitals NHS Trust
- Registry
-
NCT01882556 -
2010-021257-39 -
ISRCTN57435427
-
- Other papers using this trial's data
- Can the early use of botulinum toxin in post stroke spasticity reduce contracture development? A randomised controlled trial
- Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01882556. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Use of Botulinum Toxin in Spasticity Post Stroke.
- Acronym
- EUBoSS
- Condition
- Stroke
- Condition
- Muscle Spasticity
- Condition
- Contracture
- Intervention (Drug)
- onabotulinumtoxinA
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sandwell & West Birmingham Hospitals NHS Trust
- Collaborator
- Keele University
- Collaborator
- Stroke Research Network
Record details
- Record id
cardio:ct-nct01882556- Content hash
d9612b5e26fe467c02b09e06dba66430bfbac78608bbe9526c83b943e0f41712